Grant: Doctoral: Vanier Canada Graduate Scholarships
McMaster University
$150,000.00
Preclinical assessment of a novel Chlamydia vaccine
EF 2016-17
Résumé
Chlamydia trachomatis infections are the most prevalent sexually transmitted bacterial infections in many developed countries, including Canada. Globally, the World Health Organization estimates that 130 million new cases of C. trachomatis infection occur each year, with the highest incidence occurring in the most impoverished regions of the world, where adequate control programs are significantly lacking. C. trachomatis infections in women can lead to a number of complications, including pelvic inflammatory disease and infertility. Alarmingly, studies have shown that asymptomatic infections occur in up to 90% of women, leaving them even more susceptible to developing serious complications, as they do not have an impetus to seek medical help. The high rate of asymptomatic infections, taken together with the severity of the infection induced pathology, suggests that controlling C. trachomatis infections requires a vaccine, despite the availability of antibiotics. The type III secretion (T3S) system is used by some pathogenic bacteria to ensure successful infection, and are excellent vaccine candidates due to the nature of their structure and function. Recently, we have shown that animals immunized with chlamydial T3S components were protected against infection and disease. Given the success of this study, it would be prudent to further explore the use of T3S components in a vaccine against C. trachomatis using more relevant animal models. In that model, we aim to 1) optimize our vaccine strategy, 2) understand the nature of the immune response elicited by our vaccine, and 3) identify the immune correlates of protection. Our research could advance our understanding of Chlamydia infections and help bring new C. trachomatis vaccines into clinical trials.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
361877
Name
Liang Steven
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Preclinical assessment of a novel Chlamydia vaccine
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Chlamydia Vaccine; Immunology; Pelvic Inflammatory Disease; Sexually Transmitted Infections; Type Iii Secretion
Abstract
Chlamydia trachomatis infections are the most prevalent sexually transmitted bacterial infections in many developed countries, including Canada. Globally, the World Health Organization estimates that 130 million new cases of C. trachomatis infection occur each year, with the highest incidence occurring in the most impoverished regions of the world, where adequate control programs are significantly lacking. C. trachomatis infections in women can lead to a number of complications, including pelvic inflammatory disease and infertility. Alarmingly, studies have shown that asymptomatic infections occur in up to 90% of women, leaving them even more susceptible to developing serious complications, as they do not have an impetus to seek medical help. The high rate of asymptomatic infections, taken together with the severity of the infection induced pathology, suggests that controlling C. trachomatis infections requires a vaccine, despite the availability of antibiotics. The type III secretion (T3S) system is used by some pathogenic bacteria to ensure successful infection, and are excellent vaccine candidates due to the nature of their structure and function. Recently, we have shown that animals immunized with chlamydial T3S components were protected against infection and disease. Given the success of this study, it would be prudent to further explore the use of T3S components in a vaccine against C. trachomatis using more relevant animal models. In that model, we aim to 1) optimize our vaccine strategy, 2) understand the nature of the immune response elicited by our vaccine, and 3) identify the immune correlates of protection. Our research could advance our understanding of Chlamydia infections and help bring new C. trachomatis vaccines into clinical trials.
Competitiondate
201611
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Liang, Steven
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~